Cholesterol-Lowering Drug May Prevent Progression of Parkinson.Summary: TEHRAN (FNA)- Results of a new study by neurological researchers at Rush University Medical Center showed that a widely used cholesterol-lowering drug may prevent progression of Parkinson's disease. The study showed that Simvastatin simvastatin /sim·va·stat·in/ (sim´vah-stat?in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the risks associated , a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further.Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease."Statins are one of the most widely used cholesterol-lowering drugs throughout the world," said study author Kalipada Pahan, PhD, professor of neurological sciences at Rush University Medical Center. "This may be a safer approach to halt the disease progression in Parkinson's patients," Pahan added.Pahan and colleagues from Rush, along with researchers at the University of Nebraska Medical Center In 1991, a technology transfer office was created known as UNeMed. In 1997, the UNMC hospital merged with the nearby hospital operated by Clarkson College to become what was later renamed The Nebraska Medical Center. in Omaha published these findings in the Journal of Neurosciences.The authors have shown that the activity of one protein called p21Ras is increased very early in the midbrain midbrain: see brain. of mice with Parkinson's pathology.Simvastatin enters into the brain and blocks the activity of the p21Ras protein and other associated toxic molecules, and goes on to protect the neurons, normalize normalize to convert a set of data by, for example, converting them to logarithms or reciprocals so that their previous non-normal distribution is converted to a normal one. neurotransmitter levels, and improves the motor functions in the mice with Parkinson's."Understanding how the disease works is important to developing effective drugs that protect the brain and stop the progression of Parkinson's," Pahan said."If we are able to replicate these results in Parkinson's patients in the clinical setting, it would be a remarkable advance in the treatment of this devastating neurodegenerative disease," the author noted.The study was supported by grants from National Institutes of Health and Michael J. Fox Foundation for Parkinson's Research.Parkinson's is a slowly progressive disease that affects a small area of cells within the mid-brain known as the substantia nigra. Gradual degeneration of these cells causes a reduction in dopamine dopamine (dōp`əmēn), one of the intermediate substances in the biosynthesis of epinephrine and norepinephrine. See catecholamine. dopamine One of the catecholamines, widely distributed in the central nervous system. , which is a vital chemical neurotransmitter. The decrease in dopamine results in one or more of the classic signs of Parkinson's disease that includes, resting tremor on one side of the body, generalized slowness of movement, stiffness of limbs, and gait or balance problems. The cause of Parkinson's disease is unknown. Both environmental and genetic causes of the disease have been postulated.Parkinson's disease affects about 1.2 million patients in the United States and Canada. Although 15 percent of patients are diagnosed before age 50, it is generally considered a disease that targets older adults, affecting one of every 100 persons over the age of 60. This disease appears to be slightly more common in men than women. 2006 Fars News Agency Fars News Agency (FNA) is an Iranian news agency. It was officially launched in Tehran in February 2002 to "promote the principles of the Islamic Revolution and safeguard national interests". . All rights reserved Provided by Syndigate.info an Albawaba.com company |
|
||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion